GE医疗和Sigma生物获CRISPR/Cas9相关知识产权

2014-12-08 佚名不详

4日，博德研究所授予GE医疗和Sigma生物CRISPR/Cas9相关知识产权用于研究应用。据此，GE医疗和Sigma生物将获得博德研究所的CRISPR/Cas9专利组合，其中包括由博德研究所的Feng Zhang开创的利用病人真核细胞进行基因编辑的技术。此外，博德许可GE医疗发展其最新开创的Dharmacon Edit-R CRISPR/Cas9基因编辑系统用于建立永久的可遗传的基

4日，博德研究所授予GE医疗和Sigma生物CRISPR/Cas9相关知识产权用于研究应用。

据此，GE医疗和Sigma生物将获得博德研究所的CRISPR/Cas9专利组合，其中包括由博德研究所的Feng Zhang开创的利用病人真核细胞进行基因编辑的技术。

此外，博德许可GE医疗发展其最新开创的Dharmacon Edit-R CRISPR/Cas9基因编辑系统用于建立永久的可遗传的基因敲除细胞模型（gene knockouts cells）。而Sigma生物将在产权许可范围内创建可私人定制的慢病毒CRISPR克隆。同时，Sigma也是博德Mission shRNA and ORF libraries文库的独家经销商。授权交易的具体条款没有被披露。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (8)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1700370, encodeId=d7ec1e003704b, content=<a href='/topic/show?id=a40c9525be' target=_blank style='color:#2F92EE;'>#IgM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9525, encryptionId=a40c9525be, topicName=IgM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e80a30065003, createdName=yhy100210, createdTime=Sun Mar 15 06:10:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950092, encodeId=00ba1950092eb, content=<a href='/topic/show?id=f98b15504d8' target=_blank style='color:#2F92EE;'>#RISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15504, encryptionId=f98b15504d8, topicName=RISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Fri Jan 16 03:10:00 CST 2015, time=2015-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275821, encodeId=6f1212e5821d4, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341218, encodeId=131913412187c, content=<a href='/topic/show?id=e9c45226b3' target=_blank style='color:#2F92EE;'>#CRISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5226, encryptionId=e9c45226b3, topicName=CRISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364977, encodeId=01c113649e76b, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394706, encodeId=1f911394e067e, content=<a href='/topic/show?id=6aa8e9794e' target=_blank style='color:#2F92EE;'>#GE医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7979, encryptionId=6aa8e9794e, topicName=GE医疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591931, encodeId=9091159193183, content=<a href='/topic/show?id=271be3162a8' target=_blank style='color:#2F92EE;'>#知识产权#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73162, encryptionId=271be3162a8, topicName=知识产权)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5d18047377, createdName=lixiaol, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624732, encodeId=99091624e32ed, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=)]
2015-03-15 yhy100210

#IgM#

32 0
[GetPortalCommentsPageByObjectIdResponse(id=1700370, encodeId=d7ec1e003704b, content=<a href='/topic/show?id=a40c9525be' target=_blank style='color:#2F92EE;'>#IgM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9525, encryptionId=a40c9525be, topicName=IgM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e80a30065003, createdName=yhy100210, createdTime=Sun Mar 15 06:10:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950092, encodeId=00ba1950092eb, content=<a href='/topic/show?id=f98b15504d8' target=_blank style='color:#2F92EE;'>#RISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15504, encryptionId=f98b15504d8, topicName=RISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Fri Jan 16 03:10:00 CST 2015, time=2015-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275821, encodeId=6f1212e5821d4, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341218, encodeId=131913412187c, content=<a href='/topic/show?id=e9c45226b3' target=_blank style='color:#2F92EE;'>#CRISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5226, encryptionId=e9c45226b3, topicName=CRISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364977, encodeId=01c113649e76b, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394706, encodeId=1f911394e067e, content=<a href='/topic/show?id=6aa8e9794e' target=_blank style='color:#2F92EE;'>#GE医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7979, encryptionId=6aa8e9794e, topicName=GE医疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591931, encodeId=9091159193183, content=<a href='/topic/show?id=271be3162a8' target=_blank style='color:#2F92EE;'>#知识产权#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73162, encryptionId=271be3162a8, topicName=知识产权)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5d18047377, createdName=lixiaol, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624732, encodeId=99091624e32ed, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=)]
2015-01-16 rebeccajiejie

#RISPR/Cas9#

28 0
[GetPortalCommentsPageByObjectIdResponse(id=1700370, encodeId=d7ec1e003704b, content=<a href='/topic/show?id=a40c9525be' target=_blank style='color:#2F92EE;'>#IgM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9525, encryptionId=a40c9525be, topicName=IgM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e80a30065003, createdName=yhy100210, createdTime=Sun Mar 15 06:10:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950092, encodeId=00ba1950092eb, content=<a href='/topic/show?id=f98b15504d8' target=_blank style='color:#2F92EE;'>#RISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15504, encryptionId=f98b15504d8, topicName=RISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Fri Jan 16 03:10:00 CST 2015, time=2015-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275821, encodeId=6f1212e5821d4, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341218, encodeId=131913412187c, content=<a href='/topic/show?id=e9c45226b3' target=_blank style='color:#2F92EE;'>#CRISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5226, encryptionId=e9c45226b3, topicName=CRISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364977, encodeId=01c113649e76b, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394706, encodeId=1f911394e067e, content=<a href='/topic/show?id=6aa8e9794e' target=_blank style='color:#2F92EE;'>#GE医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7979, encryptionId=6aa8e9794e, topicName=GE医疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591931, encodeId=9091159193183, content=<a href='/topic/show?id=271be3162a8' target=_blank style='color:#2F92EE;'>#知识产权#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73162, encryptionId=271be3162a8, topicName=知识产权)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5d18047377, createdName=lixiaol, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624732, encodeId=99091624e32ed, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=)]
2014-12-10 yuandd

#CRISPR#

29 0
[GetPortalCommentsPageByObjectIdResponse(id=1700370, encodeId=d7ec1e003704b, content=<a href='/topic/show?id=a40c9525be' target=_blank style='color:#2F92EE;'>#IgM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9525, encryptionId=a40c9525be, topicName=IgM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e80a30065003, createdName=yhy100210, createdTime=Sun Mar 15 06:10:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950092, encodeId=00ba1950092eb, content=<a href='/topic/show?id=f98b15504d8' target=_blank style='color:#2F92EE;'>#RISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15504, encryptionId=f98b15504d8, topicName=RISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Fri Jan 16 03:10:00 CST 2015, time=2015-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275821, encodeId=6f1212e5821d4, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341218, encodeId=131913412187c, content=<a href='/topic/show?id=e9c45226b3' target=_blank style='color:#2F92EE;'>#CRISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5226, encryptionId=e9c45226b3, topicName=CRISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364977, encodeId=01c113649e76b, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394706, encodeId=1f911394e067e, content=<a href='/topic/show?id=6aa8e9794e' target=_blank style='color:#2F92EE;'>#GE医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7979, encryptionId=6aa8e9794e, topicName=GE医疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591931, encodeId=9091159193183, content=<a href='/topic/show?id=271be3162a8' target=_blank style='color:#2F92EE;'>#知识产权#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73162, encryptionId=271be3162a8, topicName=知识产权)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5d18047377, createdName=lixiaol, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624732, encodeId=99091624e32ed, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=)]
2014-12-10 haouestc

#CRISPR/Cas9#

25 0
[GetPortalCommentsPageByObjectIdResponse(id=1700370, encodeId=d7ec1e003704b, content=<a href='/topic/show?id=a40c9525be' target=_blank style='color:#2F92EE;'>#IgM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9525, encryptionId=a40c9525be, topicName=IgM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e80a30065003, createdName=yhy100210, createdTime=Sun Mar 15 06:10:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950092, encodeId=00ba1950092eb, content=<a href='/topic/show?id=f98b15504d8' target=_blank style='color:#2F92EE;'>#RISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15504, encryptionId=f98b15504d8, topicName=RISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Fri Jan 16 03:10:00 CST 2015, time=2015-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275821, encodeId=6f1212e5821d4, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341218, encodeId=131913412187c, content=<a href='/topic/show?id=e9c45226b3' target=_blank style='color:#2F92EE;'>#CRISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5226, encryptionId=e9c45226b3, topicName=CRISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364977, encodeId=01c113649e76b, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394706, encodeId=1f911394e067e, content=<a href='/topic/show?id=6aa8e9794e' target=_blank style='color:#2F92EE;'>#GE医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7979, encryptionId=6aa8e9794e, topicName=GE医疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591931, encodeId=9091159193183, content=<a href='/topic/show?id=271be3162a8' target=_blank style='color:#2F92EE;'>#知识产权#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73162, encryptionId=271be3162a8, topicName=知识产权)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5d18047377, createdName=lixiaol, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624732, encodeId=99091624e32ed, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=)]
2014-12-10 respect

#Cas9#

31 0
[GetPortalCommentsPageByObjectIdResponse(id=1700370, encodeId=d7ec1e003704b, content=<a href='/topic/show?id=a40c9525be' target=_blank style='color:#2F92EE;'>#IgM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9525, encryptionId=a40c9525be, topicName=IgM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e80a30065003, createdName=yhy100210, createdTime=Sun Mar 15 06:10:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950092, encodeId=00ba1950092eb, content=<a href='/topic/show?id=f98b15504d8' target=_blank style='color:#2F92EE;'>#RISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15504, encryptionId=f98b15504d8, topicName=RISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Fri Jan 16 03:10:00 CST 2015, time=2015-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275821, encodeId=6f1212e5821d4, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341218, encodeId=131913412187c, content=<a href='/topic/show?id=e9c45226b3' target=_blank style='color:#2F92EE;'>#CRISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5226, encryptionId=e9c45226b3, topicName=CRISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364977, encodeId=01c113649e76b, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394706, encodeId=1f911394e067e, content=<a href='/topic/show?id=6aa8e9794e' target=_blank style='color:#2F92EE;'>#GE医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7979, encryptionId=6aa8e9794e, topicName=GE医疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591931, encodeId=9091159193183, content=<a href='/topic/show?id=271be3162a8' target=_blank style='color:#2F92EE;'>#知识产权#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73162, encryptionId=271be3162a8, topicName=知识产权)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5d18047377, createdName=lixiaol, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624732, encodeId=99091624e32ed, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=)]
2014-12-10 12498cb5m13暂无昵称

#GE医疗#

50 0
[GetPortalCommentsPageByObjectIdResponse(id=1700370, encodeId=d7ec1e003704b, content=<a href='/topic/show?id=a40c9525be' target=_blank style='color:#2F92EE;'>#IgM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9525, encryptionId=a40c9525be, topicName=IgM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e80a30065003, createdName=yhy100210, createdTime=Sun Mar 15 06:10:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950092, encodeId=00ba1950092eb, content=<a href='/topic/show?id=f98b15504d8' target=_blank style='color:#2F92EE;'>#RISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15504, encryptionId=f98b15504d8, topicName=RISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Fri Jan 16 03:10:00 CST 2015, time=2015-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275821, encodeId=6f1212e5821d4, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341218, encodeId=131913412187c, content=<a href='/topic/show?id=e9c45226b3' target=_blank style='color:#2F92EE;'>#CRISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5226, encryptionId=e9c45226b3, topicName=CRISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364977, encodeId=01c113649e76b, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394706, encodeId=1f911394e067e, content=<a href='/topic/show?id=6aa8e9794e' target=_blank style='color:#2F92EE;'>#GE医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7979, encryptionId=6aa8e9794e, topicName=GE医疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591931, encodeId=9091159193183, content=<a href='/topic/show?id=271be3162a8' target=_blank style='color:#2F92EE;'>#知识产权#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73162, encryptionId=271be3162a8, topicName=知识产权)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5d18047377, createdName=lixiaol, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624732, encodeId=99091624e32ed, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=)]
2014-12-10 lixiaol

#知识产权#

0 0
[GetPortalCommentsPageByObjectIdResponse(id=1700370, encodeId=d7ec1e003704b, content=<a href='/topic/show?id=a40c9525be' target=_blank style='color:#2F92EE;'>#IgM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9525, encryptionId=a40c9525be, topicName=IgM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e80a30065003, createdName=yhy100210, createdTime=Sun Mar 15 06:10:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950092, encodeId=00ba1950092eb, content=<a href='/topic/show?id=f98b15504d8' target=_blank style='color:#2F92EE;'>#RISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15504, encryptionId=f98b15504d8, topicName=RISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Fri Jan 16 03:10:00 CST 2015, time=2015-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275821, encodeId=6f1212e5821d4, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341218, encodeId=131913412187c, content=<a href='/topic/show?id=e9c45226b3' target=_blank style='color:#2F92EE;'>#CRISPR/Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5226, encryptionId=e9c45226b3, topicName=CRISPR/Cas9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364977, encodeId=01c113649e76b, content=<a href='/topic/show?id=3f66412ebd' target=_blank style='color:#2F92EE;'>#Cas9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4127, encryptionId=3f66412ebd, topicName=Cas9)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394706, encodeId=1f911394e067e, content=<a href='/topic/show?id=6aa8e9794e' target=_blank style='color:#2F92EE;'>#GE医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7979, encryptionId=6aa8e9794e, topicName=GE医疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1591931, encodeId=9091159193183, content=<a href='/topic/show?id=271be3162a8' target=_blank style='color:#2F92EE;'>#知识产权#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73162, encryptionId=271be3162a8, topicName=知识产权)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5d18047377, createdName=lixiaol, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624732, encodeId=99091624e32ed, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Wed Dec 10 01:10:00 CST 2014, time=2014-12-10, status=1, ipAttribution=)]
2014-12-10 yaanren

#Cas#

27 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

检验

GE医疗和Sigma生物获CRISPR/Cas9相关知识产权

相关资讯

科室

工具

服务